|
시장보고서
상품코드
2040510
식욕 증진제 시장 규모, 점유율 및 동향 분석 보고서 : 약리학적 분류별, 적응증별, 투여 경로별, 유통 채널별, 지역별 및 부문별 예측(2026-2033년)Appetite Stimulant Market Size, Share & Trends Analysis Report By Pharmacological Class, By Indication, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033 |
||||||
식욕 증진제 시장 요약
세계의 식욕 증진제 시장 규모는 2025년에 17억 3,000만 달러로 추계되며, 2033년까지 29억 달러에 달할 것으로 예측됩니다.
2026-2033년 CAGR 6.76%로 성장할 것으로 예상됩니다. 이 시장은 식욕감퇴와 의도치 않은 체중 감소로 고통받는 환자들의 미충족 수요에 대응하는 시장입니다.
이 시장은 특히 질병 관리와 회복기에 환자 예후를 개선하는 데 매우 중요한 역할을 하고 있습니다. 삶의 질(QOL)과 지지요법에 대한 관심이 높아짐에 따라 헬스케어 시스템 전반에서 식욕 증진 솔루션의 중요성이 더욱 커지고 있습니다. 또한 의료비 증가와 포괄적인 환자 관리에 대한 관심이 높아진 것도 이 시장의 성장에 기여하고 있습니다.
식욕증진제 시장은 의도치 않은 체중 감소와 영양실조를 유발하는 암, HIV/에이즈, 신경성 식욕부진증 등 만성질환의 유병률 증가에 힘입어 꾸준한 성장세를 보이고 있습니다. 임상 영양학 및 지지요법에 대한 인식이 높아짐에 따라 의료진은 포괄적인 치료 계획에 식욕 증진제를 포함시키고 있습니다. 코르티코스테로이드, 카나비노이드, 프로게스틴과 같은 의약품이 널리 처방되고 있지만, 보다 안전한 장기적인 해결책을 찾는 환자들 사이에서는 천연 및 허브 기반 대안이 각광받고 있습니다. 노화에 따른 생리적 변화로 식욕 감퇴를 겪기 쉬운 고령 인구의 증가도 시장 수요를 더욱 부추기고 있습니다. 또한 병원과 장기요양시설은 안정적인 소비를 지원하는 주요 최종사용자가 되었습니다. 신흥 시장에서도 의료 인프라 개선과 치료 접근성 향상을 배경으로 채택이 확대되고 있습니다.
또한 이 산업은 환자의 복약 순응도와 효능을 향상시키기 위해 약물 제형과 약물전달 메커니즘의 혁신을 통해 진화하고 있습니다. 각 업체들은 기존 식욕 증진제에 대한 우려를 해소하기 위해 부작용이 적은 표적 치료제를 개발하기 위한 연구에 투자하고 있습니다. 의료용 대마, 특히 도로나비놀을 함유한 제품에 대한 관심이 높아지면서 특히 종양학 및 완화 치료 분야에서 식욕 증진을 위한 새로운 길이 열리고 있습니다. 규제 당국의 승인과 임상 시험은 계속해서 경쟁 구도를 형성하고 지역별로 제품 공급 상황에 영향을 미치고 있습니다. 이와 함께 비타민과 허브 추출물을 통해 자연적으로 식욕을 증진하도록 고안된 보충제로 인해 뉴트리슈티컬(기능성 식품) 분야도 빠르게 성장하고 있습니다. 디지털 헬스와의 통합과 맞춤형 영양 접근법도 점점 더 활발해지고 있으며, 환자 개개인에 맞는 치료 전략을 가능하게 하고 있습니다. 전반적으로 식욕 증진제 산업은 질병 부담의 증가와 지속적인 치료법 발전에 힘입어 중등도에서 강한 성장세를 보일 것으로 예상됩니다.
자주 묻는 질문
목차
제1장 조사 방법과 범위
제2장 개요
제3장 식욕 증진제 시장 : 변수, 동향, 범위
제4장 식욕 증진제 시장 : 약리학적 분류에 기반한 사업 분석
제5장 식욕 증진제 시장 : 적응증별 비즈니스 분석
제6장 식욕 증진제 시장 : 투여 경로별 비즈니스 분석
제7장 식욕 증진제 시장 : 유통 채널별 비즈니스 분석
제8장 식욕 증진제 시장 : 지역별 추정·동향 분석
제9장 경쟁 구도
KSA 26.06.02Appetite Stimulant Market Summary
The global appetite stimulant market size was estimated at USD 1.73 billion in 2025 and is projected to reach USD 2.90 billion by 2033, growing at a CAGR of 6.76% from 2026 to 2033. The market addresses unmet needs in patients experiencing reduced appetite and unintended weight loss.
It plays a critical role in improving patient outcomes, particularly in disease management and recovery phases. Growing emphasis on quality of life and supportive therapies has increased the relevance of appetite-enhancing solutions across healthcare systems. The market also benefits from rising healthcare expenditure and a greater focus on holistic patient care.
The appetite stimulant market is experiencing steady growth, driven by the rising prevalence of chronic conditions such as Cancer, HIV/AIDS, and Anorexia Nervosa that often lead to unintended weight loss and malnutrition. Increasing awareness of clinical nutrition and supportive care has encouraged healthcare providers to incorporate appetite stimulants into comprehensive treatment plans. Pharmaceutical options, including corticosteroids, cannabinoids, and progestogens, are widely prescribed, while natural and herbal alternatives are gaining traction among patients seeking safer long-term solutions. The expanding geriatric population, which is more susceptible to appetite loss due to age-related physiological changes, further supports market demand. Additionally, hospital settings and long-term care facilities are key end users contributing to consistent consumption. Emerging markets are also witnessing increased adoption driven by improving healthcare infrastructure and greater access to treatment.
Furthermore, the industry is evolving through innovations in drug formulations and delivery mechanisms to improve patient compliance and efficacy. Companies are investing in research to develop targeted therapies with fewer side effects, addressing concerns associated with traditional appetite stimulants. The growing interest in medical cannabis, particularly products containing Dronabinol, has opened new avenues for appetite stimulation, especially in oncology and palliative care. Regulatory approvals and clinical trials continue to shape the competitive landscape, influencing product availability across regions. In parallel, the nutraceutical segment is expanding rapidly, with supplements designed to enhance appetite naturally through vitamins and herbal extracts. Digital health integration and personalized nutrition approaches are also gaining momentum, enabling tailored treatment strategies. Overall, the appetite stimulant industry is positioned for moderate to strong growth, supported by rising disease burden and ongoing therapeutic advancements.
Global Appetite Stimulant Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global appetite stimulant market report based on pharmacological class, indication, route of administration, distribution channel, and region:
- Pharmacological class Outlook (Revenue, USD Billion, 2021 - 2033)
- Progestational & Hormonal Agents
- Cannabinoids & CNS-Acting Agents
- Anabolic & Metabolic Agents
- Nutritional / Micronutrient Agents
- Others
- Indication Outlook (Revenue, USD Billion, 2021 - 2033)
- Disease-Related Cachexia
- Chronic Disease-Associated Malnutrition
- Age-Related & General Anorexia
- Pediatric Undernutrition
- Others
- Route of Administration Outlook (Revenue, USD Billion, 2021 - 2033)
- Oral
- Parenteral (Injectable)
- Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Regional Outlook (Revenue, USD Billion, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Pharmacological class
- 1.2.2. Indication
- 1.2.3. Route of Administration
- 1.2.4. Distribution Channel
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Appetite Stimulant Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis
- 3.3.4. Patent Expiry Analysis
- 3.3.5. Pricing Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
Chapter 4. Appetite Stimulant Market: Pharmacological class Business Analysis
- 4.1. Pharmacological class Market Share, 2025 & 2033
- 4.2. Pharmacological class Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Pharmacological class, 2021 to 2033 (USD Billion)
- 4.4. Progestational & Hormonal Agents
- 4.4.1. Progestational & Hormonal Agents Market, 2021 - 2033 (USD Billion)
- 4.5. Cannabinoids & CNS-Acting Agents
- 4.5.1. Cannabinoids & CNS-Acting Agents Market, 2021 - 2033 (USD Billion)
- 4.6. Anabolic & Metabolic Agents
- 4.6.1. Anabolic & Metabolic Agents Market, 2021 - 2033 (USD Billion)
- 4.7. Nutritional / Micronutrient Agents
- 4.7.1. Nutritional / Micronutrient Agents Market, 2021 - 2033 (USD Billion)
- 4.8. Others
- 4.8.1. Others Market, 2021 - 2033 (USD Billion)
Chapter 5. Appetite Stimulant Market: Indication Business Analysis
- 5.1. Indication Market Share, 2025 & 2033
- 5.2. Indication Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Billion)
- 5.4. Disease-Related Cachexia
- 5.4.1. Disease-Related Cachexia Market, 2021 - 2033 (USD Billion)
- 5.5. Chronic Disease-Associated Malnutrition
- 5.5.1. Chronic Disease-Associated Malnutrition Market, 2021 - 2033 (USD Billion)
- 5.6. Age-Related & General Anorexia
- 5.6.1. Age-Related & General Anorexia Market, 2021 - 2033 (USD Billion)
- 5.7. Pediatric Undernutrition
- 5.7.1. Pediatric Undernutrition Market, 2021 - 2033 (USD Billion)
- 5.8. Others
- 5.8.1. Others Market, 2021 - 2033 (USD Billion)
Chapter 6. Appetite Stimulant Market: Route of Administration Business Analysis
- 6.1. Route of Administration Market Share, 2025 & 2033
- 6.2. Route of Administration Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Billion)
- 6.4. Oral
- 6.4.1. Oral Market, 2021 - 2033 (USD Billion)
- 6.5. Parenteral (Injectable)
- 6.5.1. Parenteral (Injectable) Market, 2021 - 2033 (USD Billion)
Chapter 7. Appetite Stimulant Market: Distribution Channel Business Analysis
- 7.1. Distribution Channel Market Share, 2025 & 2033
- 7.2. Distribution Channel Segment Dashboard
- 7.3. Market Size & Forecasts and Trend Analysis, by Distribution channel, 2021 to 2033 (USD Billion)
- 7.4. Hospital Pharmacies
- 7.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Billion)
- 7.5. Retail Pharmacies
- 7.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Billion)
- 7.6. Others
- 7.6.1. Others Market, 2021 - 2033 (USD Billion)
Chapter 8. Appetite Stimulant Market: Regional Estimates & Trend Analysis
- 8.1. Regional Market Share Analysis, 2025 & 2033
- 8.2. Regional Market Dashboard
- 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
- 8.4. North America
- 8.4.1. North America Appetite Stimulant Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Billion)
- 8.4.2. U.S.
- 8.4.2.1. Key Country Dynamics
- 8.4.2.2. Target Disease Prevalence
- 8.4.2.3. Regulatory Framework
- 8.4.2.4. Reimbursement Framework
- 8.4.2.5. U.S. Appetite Stimulant Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.4.3. Canada
- 8.4.3.1. Key Country Dynamics
- 8.4.3.2. Target Disease Prevalence
- 8.4.3.3. Regulatory Framework
- 8.4.3.4. Reimbursement Framework
- 8.4.3.5. Canada Appetite Stimulant Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.4.4. Mexico
- 8.4.4.1. Key Country Dynamics
- 8.4.4.2. Target Disease Prevalence
- 8.4.4.3. Regulatory Framework
- 8.4.4.4. Reimbursement Framework
- 8.4.4.5. Mexico Appetite Stimulant Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5. Europe
- 8.5.1. Europe Appetite Stimulant Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5.2. UK
- 8.5.2.1. Key Country Dynamics
- 8.5.2.2. Target Disease Prevalence
- 8.5.2.3. Regulatory Framework
- 8.5.2.4. Reimbursement Framework
- 8.5.2.5. UK Appetite Stimulant Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5.3. Germany
- 8.5.3.1. Key Country Dynamics
- 8.5.3.2. Target Disease Prevalence
- 8.5.3.3. Regulatory Framework
- 8.5.3.4. Reimbursement Framework
- 8.5.3.5. Germany Appetite Stimulant Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5.4. France
- 8.5.4.1. Key Country Dynamics
- 8.5.4.2. Target Disease Prevalence
- 8.5.4.3. Regulatory Framework
- 8.5.4.4. Reimbursement Framework
- 8.5.4.5. France Appetite Stimulant Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5.5. Italy
- 8.5.5.1. Key Country Dynamics
- 8.5.5.2. Target Disease Prevalence
- 8.5.5.3. Regulatory Framework
- 8.5.5.4. Reimbursement Framework
- 8.5.5.5. Italy Appetite Stimulant Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5.6. Spain
- 8.5.6.1. Key Country Dynamics
- 8.5.6.2. Target Disease Prevalence
- 8.5.6.3. Regulatory Framework
- 8.5.6.4. Reimbursement Framework
- 8.5.6.5. Spain Appetite Stimulant Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5.7. Denmark
- 8.5.7.1. Key Country Dynamics
- 8.5.7.2. Target Disease Prevalence
- 8.5.7.3. Regulatory Framework
- 8.5.7.4. Reimbursement Framework
- 8.5.7.5. Denmark Appetite Stimulant Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5.8. Sweden
- 8.5.8.1. Key Country Dynamics
- 8.5.8.2. Target Disease Prevalence
- 8.5.8.3. Regulatory Framework
- 8.5.8.4. Reimbursement Framework
- 8.5.8.5. Sweden Appetite Stimulant Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5.9. Norway
- 8.5.9.1. Key Country Dynamics
- 8.5.9.2. Target Disease Prevalence
- 8.5.9.3. Regulatory Framework
- 8.5.9.4. Reimbursement Framework
- 8.5.9.5. Norway Appetite Stimulant Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.6. Asia Pacific
- 8.6.1. Asia Pacific Appetite Stimulant Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.6.2. Japan
- 8.6.2.1. Key Country Dynamics
- 8.6.2.2. Target Disease Prevalence
- 8.6.2.3. Regulatory Framework
- 8.6.2.4. Reimbursement Framework
- 8.6.2.5. Japan Appetite Stimulant Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.6.3. China
- 8.6.3.1. Key Country Dynamics
- 8.6.3.2. Target Disease Prevalence
- 8.6.3.3. Regulatory Framework
- 8.6.3.4. Reimbursement Framework
- 8.6.3.5. China Appetite Stimulant Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.6.4. India
- 8.6.4.1. Key Country Dynamics
- 8.6.4.2. Target Disease Prevalence
- 8.6.4.3. Regulatory Framework
- 8.6.4.4. Reimbursement Framework
- 8.6.4.5. India Appetite Stimulant Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.6.5. Australia
- 8.6.5.1. Key Country Dynamics
- 8.6.5.2. Target Disease Prevalence
- 8.6.5.3. Regulatory Framework
- 8.6.5.4. Reimbursement Framework
- 8.6.5.5. Australia Appetite Stimulant Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.6.6. South Korea
- 8.6.6.1. Key Country Dynamics
- 8.6.6.2. Target Disease Prevalence
- 8.6.6.3. Regulatory Framework
- 8.6.6.4. Reimbursement Framework
- 8.6.6.5. South Korea Appetite Stimulant Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.6.7. Thailand
- 8.6.7.1. Key Country Dynamics
- 8.6.7.2. Target Disease Prevalence
- 8.6.7.3. Regulatory Framework
- 8.6.7.4. Reimbursement Framework
- 8.6.7.5. Thailand Appetite Stimulant Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.7. Latin America
- 8.7.1. Latin America Appetite Stimulant Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.7.2. Brazil
- 8.7.2.1. Key Country Dynamics
- 8.7.2.2. Target Disease Prevalence
- 8.7.2.3. Regulatory Framework
- 8.7.2.4. Reimbursement Framework
- 8.7.2.5. Brazil Appetite Stimulant Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.7.3. Argentina
- 8.7.3.1. Key Country Dynamics
- 8.7.3.2. Target Disease Prevalence
- 8.7.3.3. Regulatory Framework
- 8.7.3.4. Reimbursement Framework
- 8.7.3.5. Argentina Appetite Stimulant Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.8. Middle East and Africa
- 8.8.1. Middle East and Africa Appetite Stimulant Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.8.2. South Africa
- 8.8.2.1. Key Country Dynamics
- 8.8.2.2. Target Disease Prevalence
- 8.8.2.3. Regulatory Framework
- 8.8.2.4. Reimbursement Framework
- 8.8.2.5. South Africa Appetite Stimulant Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.8.3. Saudi Arabia
- 8.8.3.1. Key Country Dynamics
- 8.8.3.2. Target Disease Prevalence
- 8.8.3.3. Regulatory Framework
- 8.8.3.4. Reimbursement Framework
- 8.8.3.5. Saudi Arabia Appetite Stimulant Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.8.4. UAE
- 8.8.4.1. Key Country Dynamics
- 8.8.4.2. Target Disease Prevalence
- 8.8.4.3. Regulatory Framework
- 8.8.4.4. Reimbursement Framework
- 8.8.4.5. UAE Appetite Stimulant Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.8.5. Kuwait
- 8.8.5.1. Key Country Dynamics
- 8.8.5.2. Target Disease Prevalence
- 8.8.5.3. Regulatory Framework
- 8.8.5.4. Reimbursement Framework
- 8.8.5.5. Kuwait Appetite Stimulant Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 9. Competitive Landscape
- 9.1. Participant Overview
- 9.2. Company Market Position Analysis
- 9.3. Company Categorization
- 9.4. Strategy Mapping
- 9.5. Company Profiles/Listing
- 9.5.1. Pfizer Inc.
- 9.5.1.1. Overview
- 9.5.1.2. Financial Performance
- 9.5.1.3. Product Benchmarking
- 9.5.1.4. Strategic Initiatives
- 9.5.2. Merck & Co., Inc.
- 9.5.2.1. Overview
- 9.5.2.2. Financial Performance
- 9.5.2.3. Product Benchmarking
- 9.5.2.4. Strategic Initiatives
- 9.5.3. Johnson & Johnson
- 9.5.3.1. Overview
- 9.5.3.2. Financial Performance
- 9.5.3.3. Product Benchmarking
- 9.5.3.4. Strategic Initiatives
- 9.5.4. GlaxoSmithKline plc (GSK).
- 9.5.4.1. Overview
- 9.5.4.2. Financial Performance
- 9.5.4.3. Product Benchmarking
- 9.5.4.4. Strategic Initiatives
- 9.5.5. Novartis AG
- 9.5.5.1. Overview
- 9.5.5.2. Financial Performance
- 9.5.5.3. Product Benchmarking
- 9.5.5.4. Strategic Initiatives
- 9.5.6. Sanofi S.A.
- 9.5.6.1. Overview
- 9.5.6.2. Financial Performance
- 9.5.6.3. Product Benchmarking
- 9.5.6.4. Strategic Initiatives
- 9.5.7. AbbVie Inc.
- 9.5.7.1. Overview
- 9.5.7.2. Financial Performance
- 9.5.7.3. Product Benchmarking
- 9.5.7.4. Strategic Initiatives
- 9.5.8. Teva Pharmaceutical Industries Ltd.
- 9.5.8.1. Overview
- 9.5.8.2. Financial Performance
- 9.5.8.3. Product Benchmarking
- 9.5.8.4. Strategic Initiatives
- 9.5.1. Pfizer Inc.
